Previous reports have shown that PPARβ agonists, such as GW501516, ameliorates insulin resistance by increasing the expression of the insulin receptor, of significance for treatment of insulin resistance in patients with type 2 diabetes mellitus (95). This evidence concerns the gene INSR and Insulin resistance.